Recruiting
Phase 4
Glycemic Variability of Combination Therapies in T2DM
About this study
Glycemic Variability of Combination Therapies in T2DM
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Tested
- Empagliflozin/Metformin, Anagliptin, Metformin, Empagliflozin/Linagliptin
- Sponsor
- JW Pharmaceutical
Who can join
- Age
- 19 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 3
- Minimum age: 19 years
- Study condition: Type 2 Diabetes Mellitus (T2DM)
- Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor.
Exclusion 4
- History of acute or chronic metabolic acidosis
- Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73m²)
- Severe hepatic impairment
- History of heart failure (NYHA Class III/IV)
Where
1 site, 1 recruiting
The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
Seoul, South Korea
Contact
-
Saemi Kang
82-2-840-6902 kangsm@jwhealthcare.com
Potential match only. Final eligibility is determined by the study team.